
|Videos|January 18, 2023
The Impact of Using AR Pathway Inhibitors and Docetaxel in Early Treatment of Prostate Cancer
Author(s)Stephen J. Freedland, MD
Dr Stephen J. Freedland muses on how the utilization of AR pathway inhibitors and docetaxel in earlier lines of prostate cancer treatment has impacted subsequent treatment selection in mCRPC.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
5 urologic oncology headlines you missed in Q2 2026
2
5 benign urology headlines you missed in Q2 2026
3
Helen L. Bernie, DO, MPH, on counseling patients through TRT and prostate cancer uncertainty
4
Advancing PROs to support survivor-centered NMIBC care
5














